查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197821

眼科藥物和設備市場 - 增長、趨勢和預測 (2023-2028)

Ophthalmology Drug and Device Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，眼科藥品和設備市場預計將以 5.5% 的複合年增長率註冊。

COVID-19 大流行最初對市場產生了重大影響，因為一些國家被封鎖並且與其他國家的貿易由於旅行限製而停止，導致眼科診斷下降。 疫情期間，不少眼科醫生出於警惕，暫時停業。 根據《印度眼科雜誌》2021 年 12 月發表的一篇文章，一項針對全印度眼科學會 (AIOS) 成員的調查顯示，COVID-19 對全印度的眼科保健服務產生了負面影響。 隨著 COVID-19 病例數量大幅下降，市場開始復蘇並獲得牽引力。 因此，預計在本研究的預測期內，市場將穩步增長。

推動市場增長的某些因素包括眼科疾病流行的影響、人口結構變化、眼科領域的技術進步以及老年人口的增加。 根據世界衛生組織2022年10月更新的數據，估計全球至少有22億人患有近視或遠視。 其中，至少有 10 億人已經預防或尚未解決視力喪失問題。 在這 10 億人中，有未解決的屈光不正（8840 萬）、白內障（9400 萬）、年齡相關性黃斑變性（800 萬）、青光眼（770 萬）和糖尿病性視網膜病變（390 萬）。這包括中度或重度遠視力障礙和因各種疾病（例如人類疾病）導致的失明），以及因未經治療的老花眼導致的近視力障礙（826 萬人）。 在許多國家，白內障手術是最常進行的外科手術，能夠以低成本顯著改善老年人的生活質量。 老年人口的增長和眼科疾病的高患病率正在增加對眼科設備的需求，並預見到未來的白內障手術需求對人力資源、醫院和手術中心的管理和規劃至關重要。 其他因素，如新設備和新藥的出現，以及眼科疾病發病率的增加，預計也將在預測期內推動市場。

此外，主要市場參與者的新產品發布和戰略活動對所研究市場的增長產生了積極影響。 例如，2022 年 6 月，Biogen Inc. 和 Samsung Bioepis 在美國推出了 ranibizumab nuna（Bjobiz，Biogen），這是一種參考雷珠單抗（Lucentis，Genentech）的眼科生物仿製藥。 因此，由於產品發布和合作夥伴關係，預計所研究的市場在預測期內將顯著增長。

因此，由於上述因素，預計所研究的市場在分析期內會出現增長。 然而，眼科設備和治療成本的上升，以及 FDA 對藥物批准的嚴格指導方針，可能會阻礙市場增長。

眼科藥物和設備的市場趨勢

預計青光眼細分市場在預測期內將出現顯著增長

青光眼是視力喪失和失明的最常見原因之一。 由於青光眼是一種不可逆轉的疾病，因此早期發現和治療至關重要。 隨著人口老齡化，青光眼的發病率預計將很快上升，成為市場增長的推動力。

根據印度政府 MoHFW 發布的數據，到 2021 年 3 月，青光眼將成為全球第二大失明原因，WHO 估計有 450 萬人因青光眼而失明。 . 此外，數據顯示，青光眼是印度不可逆轉失明的第一大原因，影響至少 1200 萬人，約 120 萬人因該病失明。 據估計，超過 90% 的青光眼患者在其社區中未被確診。 青光眼的高患病率預計將推動未來幾年的市場增長。

在歐洲，核性開角型青光眼造成了重大的公共衛生負擔，在不久的將來對該設備的需求可能會增加。 例如，根據 2022 年 8 月發表在 ScienceDirect 上的一篇文章，大多數青光眼患者應該定期進行積極監測和管理，以防止不可逆轉的視力喪失。 該論文進一步指出，青光眼的治療目前估計佔英國醫院眼科服務門診工作量的 20%，每年有超過 100 萬與青光眼相關的英國醫院眼科就診。他說患者正在就診。 由於人口老齡化、獲得視力測試的機會增加以及眼科檢查（包括視網膜成像）的嚴格程度提高，預計與青光眼相關的門診就診人數將會增加。

此外，根據 2022 年 5 月發表在 Journal of Ophthalmology 上的一篇研究論文，青光眼是最常見的威脅視力的眼病之一。 它通常伴有眼內壓 (IOP) 過高，眼睛（視）神經的衰竭可導致視力喪失甚至失明。 此外，由於青光眼是一種主要影響老年人的疾病，預計由於老年人口增加等因素，患者人數也會增加。

因此，青光眼的高發病率將增加對藥品和器械的需求，預計在預測期內將出現大幅增長。

預計在預測期內北美將佔據很大的市場份額

由於完善的醫療保健設施、不斷增長的老年人口以及大公司的存在，預計北美地區將出現顯著增長。 由於美國老年人口不斷增加、視力矯正的趨勢及其在重要人群中的使用，美國大多數類型眼鏡的銷售率都有所提高。 美國在北美的眼科診斷設備市場佔有很大份額。 隨著人口老齡化的迅速增長以及由於高壓力和不健康的生活方式導致的眼病患病率上升可能導致糖尿病視網膜病變等疾病，市場預計將增長。 人口老齡化加劇，更易患眼疾，市場增長基數有望進一步擴大。

青光眼、白內障、黃斑變性和糖尿病性視網膜病變等眼科疾病的患病率正在上升，預計將在預測期內推動市場。 根據青光眼研究基金會 2022 年 2 月的數據，估計有超過 300 萬美國人患有青光眼。 然而，只有一半的人知道這種疾病。 美國有超過12萬人因青光眼失明，佔所有失明人數的9%至12%。 因此，眼科疾病的增加將導致對藥品和設備的需求增加。

大量產品發布、市場參與者高度集中或製造商在美國的存在是推動所研究的該國市場增長的一些因素。 例如，2022年4月，山德士推出仿製藥複方滴眼液，酒石酸溴莫尼定/馬來酸塞嗎洛爾滴眼液0.2%/0.5%。 它是 AbbVie 的 Comvigan 的 AB 級仿製藥，可降低美國高眼壓症（高眼壓症）患者的眼內壓。 此外，2021 年 12 月，Allergan推出了 VUITY（鹽酸毛果芸香鹼滴眼液 1.25%），這是美國 FDA 批准的第一個也是唯一一個治療老花眼的滴眼液。 這些持續推出的產品預計將推動該地區的市場增長。

因此，由於上述因素，北美地區的市場有望增長。

眼科藥品和器械市場的競爭對手分析

眼科藥物和設備市場較為分散。 競爭格局包括對少數具有市場份額的知名國際和本地公司的分析。 它由 Alcon Inc.、Bausch Health Companies Inc.、Carl Zeiss Meditec AG、Essilor International SA、Haag-Streit Group (Metall Zug AG)、Johnson & Johnson、Nidek、Topcon Corporation 和 Ziemer Group AG 等主要公司組成。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 人口結構的變化及其對眼科疾病患病率的影響
    • 眼科領域的技術進步
  • 市場製約因素
    • 眼科設備和治療費用高昂
    • 嚴格的 FDA 藥物審批指南
  • 波特的五力分析
    • 供應商的議價能力
    • 買方/消費者議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品分類
    • 設備
      • 手術器械
      • 人工晶狀體
      • 眼科激光
      • 其他手術設備
      • 診斷設備
    • 藥物
      • 青光眼藥物
      • 視網膜疾病的治療
      • 乾眼症治療
      • 過敏性結膜炎/炎症藥物
      • 其他藥物
  • 按疾病分類
    • 青光眼
    • 白內障
    • 年齡相關性黃斑變性
    • 炎症性疾病
    • 屈光矯正
    • 其他疾病
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Alcon Inc.
    • Bausch Health Companies Inc.
    • Carl Zeiss Meditec AG
    • Essilor International SA
    • Haag-Streit Group（Metall Zug AG）
    • Johnson & Johnson
    • Nidek Co. Ltd
    • Topcon Corporation
    • NIDEK Co. Ltd
    • Lumenis Ltd
    • Ziemer Ophthalmic Systems AG

第第七章市場機會與未來趨勢

簡介目錄
Product Code: 48323

The ophthalmology drug and device market is expected to witness a CAGR of 5.5% during the forecast period.

The COVID-19 pandemic had a significant impact on the market initially as several countries were in lockdown, and trades were suspended with other countries with travel restrictions, leading to a decline in eye diagnoses. As a cautionary measure, many ophthalmologists temporarily closed their practices during the pandemic. According to an article published by the Indian Journal of Ophthalmology in December 2021, a survey was conducted among the All India Ophthalmological Society (AIOS) members, which stated that COVID-19 had adversely affected ophthalmic care services across the whole of India. As the number of COVID-19 cases has decreased significantly, the market has recovered and started to gain traction. Hence, the market is expected to have stable growth during the forecast period of the study.

Certain factors driving the market's growth include the impact of the prevalence of eye disease, demographic shift, technological advancements in the field of ophthalmology, and the rising geriatric population. According to the data updated by WHO in October 2022, it is estimated at least 2.2 billion people will have a near or distant vision impairment globally. Among these, at least 1 billion people's vision impairment could have been prevented or yet to get addressed. These 1 billion people include those with moderate or severe distance vision impairment or blindness due to various diseases like unaddressed refractive error (88.4 million), cataract (94 million), age-related macular degeneration (8 million), glaucoma (7.7 million), diabetic retinopathy (3.9 million), as well as near vision impairment caused by unaddressed presbyopia (826 million). In many countries, cataract surgery is the most common surgical procedure performed, significantly improving the quality of life of the elderly population at low costs. An increase in the elderly population and the high prevalence of ophthalmic disorders increases the demand for ophthalmological devices and projects the future cataract surgery needs vital for human health resources, hospitals, and surgical centre management and planning. Other factors, such as the availability of new devices and new drugs and the growing incidence of eye disease, are also expected to drive the market over the forecast period.

In addition, new product launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched ranibizumab-nuna (Byooviz, Biogen), an ophthalmic biosimilar referencing ranibizumab (Lucentis, Genentech) in the US. Thus, due to the product launches and partnerships, the studied market is expected to grow significantly over the forecast period.

Therefore, owing to the factors above, the studied market is anticipated to witness growth over the analysis period. However, the higher cost of ophthalmic devices and treatment and strict FDA guidelines for drug approval is likely to impede the market's growth.

Ophthalmology Drug & Device Market Trends

The Glaucoma Segment is Expected to Show Significant Growth in the Forecast Years

Globally, glaucoma is one of the most common causes of vision loss or blindness. Being irreversible, the early detection and management of glaucoma are of utmost importance. With increasing ageing, the incidence of glaucoma is expected to rise shortly, driving market growth.

According to the data published by the MoHFW, Government of India, in March 2021, glaucoma is estimated to be the second most common cause of blindness worldwide, and WHO estimated that 4.5 million people are blind due to glaucoma. The data further revealed that in India, glaucoma is the leading cause of irreversible blindness, with a minimum of 12 million people affected and nearly 1.2 million people blind from the disease. It is also estimated that more than 90% of glaucoma cases are undiagnosed in the community. With the high prevalence of glaucoma, it is expected to drive market growth in the coming years.

Primary open-angle glaucoma is a significant public health burden in Europe, likely increasing the demand for devices soon. For instance, as per an article published by ScienceDirect in August 2022, most individuals affected with glaucoma require regular active monitoring and management to prevent irreversible vision loss. The article further states glaucoma care currently accounts for an estimated 20% workload of hospital eye service outpatients in the UK, with over 1 million glaucoma-related outpatient visits made each year to hospital eye services in England. With an ageing population, increased access to sight testing, and more rigorous optometry screening (including retinal imaging), the number of glaucoma-related outpatient visits is expected to rise.

Furthermore, according to a research article published by the Journal of Ophthalmology in May 2022, glaucoma is considered one of the most frequent vision-threatening eye diseases. It is frequently associated with excessive Intraocular Pressure (IOP) that causes vision loss and possibly blindness if the eye's (optic) nerve fails. Factors such as the increasing geriatric population are also expected to increase the number of glaucoma patients as the disorder primarily affects older people.

Thus, the high incidence of glaucoma is expected to raise demand for drugs and devices and show significant growth over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

Due to the presence of well-established healthcare facilities, the rise in the geriatric population in the region, and the presence of large companies, the North American region is expected to grow significantly. Due to the constant increase in the American elderly population, a move toward vision correction and its usage among crucial demographics, an increase in rates for most eyewear types was observed in the US. The United States holds a substantial share of the ophthalmology diagnostics market in the North American region. The market is expected to grow due to the rapidly increasing geriatric population and the rising prevalence of eye diseases due to high stress and unhealthy lifestyles, which can result in conditions such as diabetic retinopathy. The geriatric population is increasing, and it is more susceptible to developing eye diseases, which is further anticipated to widen the base for market growth.

There has been a rising prevalence of eye diseases, such as glaucoma, cataract, macular degeneration, and diabetic retinopathy, which is anticipated to propel the market over the forecast period. As per the data by the Glaucome Research Foundation in February 2022, it is estimated that over 3 million Americans have glaucoma. Still, only half of those are aware of the disease. In the United States, more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Hence, an increase in eye disorders will lead to a growing demand for drugs and devices.

Key product launches, high concentration of market players, or manufacturers' presence in the United States are some factors driving the studied market growth in the country. For instance, in April 2022, Sandoz launched its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%. It is an AB-rated generic equivalent to AbbVie's COMBIGAN to lower eye pressure in patients with ocular hypertension (high eye pressure) in the United States. Furthermore, in December 2021, Allergan launched VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the US FDA to treat presbyopia. These continuous product launches in the region are anticipated to drive market growth in the country.

Therefore, owing to the factors above, the growth of the studied market is anticipated in the North American region.

Ophthalmology Drug & Device Market Competitor Analysis

The ophthalmology drug and device market are moderately fragmented in nature. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. It consists of major players such as Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Essilor International SA, Haag-Streit Group (Metall Zug AG), Johnson & Johnson, Nidek Co. Ltd, Topcon Corporation, Ziemer Group AG, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demographic Shift and Impact of Prevalence of Eye Disease
    • 4.2.2 Technological Advancements in the Field of Ophthalmology
  • 4.3 Market Restraints
    • 4.3.1 Higher Cost of the Ophthalmic Devices and Treatment
    • 4.3.2 Strict FDA Guidelines for Drug Approval
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Devices
      • 5.1.1.1 Surgical Devices
      • 5.1.1.1.1 Intraocular Lenses
      • 5.1.1.1.2 Ophthalmic Lasers
      • 5.1.1.1.3 Other Surgical Devices
      • 5.1.1.2 Diagnostic Devices
    • 5.1.2 Drugs
      • 5.1.2.1 Glaucoma Drugs
      • 5.1.2.2 Retinal Disorder Drugs
      • 5.1.2.3 Dry Eye Drugs
      • 5.1.2.4 Allergic Conjunctivitis and Inflammation Drugs
      • 5.1.2.5 Other Drugs
  • 5.2 By Disease
    • 5.2.1 Glaucoma
    • 5.2.2 Cataract
    • 5.2.3 Age-Related Macular Degeneration
    • 5.2.4 Inflammatory Diseases
    • 5.2.5 Refractive Disorders
    • 5.2.6 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alcon Inc.
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 Carl Zeiss Meditec AG
    • 6.1.4 Essilor International SA
    • 6.1.5 Haag-Streit Group (Metall Zug AG)
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Nidek Co. Ltd
    • 6.1.8 Topcon Corporation
    • 6.1.9 NIDEK Co. Ltd
    • 6.1.10 Lumenis Ltd
    • 6.1.11 Ziemer Ophthalmic Systems AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS